Document is current

Article History

Received: 25 March 2025

Accepted: 22 July 2025

First Online: 10 October 2025

Declarations

:

: All authors have no conflict of interest regarding the submitted work. Outside of the submitted work, the following relationships are reported: MH: honoraria: Sanofi.MSR: consulting or advisory role: BMS, Amgen, GSK, Janssen, Sanofi, Pfizer, AbbVie, Novartis, and Roche; research funding: Sanofi; travel accommodation and expenses: BMS, AbbVie, Janssen, Sanofi, and GSK; Honoraria: BMS, Janssen, GSK, AbbVie, and Sanofi; receipt of equipment, materials, drugs, medical writing, gifts or other services: Novartis and Sanofi.SS: travel grants or honoraria: Celgene, BMS, Janssen, Takeda, and Amgen. BB: honoraria: Janssen, GSK, AMGEN, Pfizer, Oncopeptides, and Sanofi.UG: stock and other ownership interests: Biontech; honoraria: Boehringer Ingelheim, Amgen, AstraZeneca, Bristol-Myers Squibb, MSD Oncology, Sanofi Aventis GmbH, Fujifilm, Cellrion, Ipsen, and Novartis; consulting or advisory role: Amgen and MSD Oncology; research funding: Ipsen and Macrogenics; travel, accomodations or expenses: Boehringer Ingelheim and GSK.JD: advisory board and travel support: Amgen, BMS, Janssen, Sanofi, and Takeda; honoraria: Amgen, BMS, Janssen, and Sanofi.LU: advisory board: EasyRadiology; speaker: Siemens Healthineers and Bayer Healthcare. HPS: consulting fee or honoraria: Siemens, Curagita, Profound, and Bayer; travel support: Siemens, Curagita, Profound, and Bayer; board member: Curagita; consultancy: Curagita and Bayer; payment for lectures: Siemens, Curagita, Profound, and Bayer.HG: grants and/or provision of investigational medicinal products: Amgen, Array Biopharma/Pfizer, BMS, Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Mundipharma GmbH, and Sanofi; research support: Amgen, BMS, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Karyopharm, Janssen, Incyte, Millenium Pharmaceuticals Inc., Molecular Partners, Merck Sharp and Dohme, MorphoSys AG, Pfizer, Sanofi, Takeda, and Novartis; advisory board: Adaptive Biotechnology, Amgen, BMS, Janssen, and Sanofi; honoraria: Amgen, BMS, Chugai, GlaxoSmithKline, Janssen, Novartis, Sanofi, and Pfizer. EKM: consulting or advisory role: Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi, Stemline, and Takeda; honoraria: Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi, Stemline, and Takeda; research funding: Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, and Takeda; travel accommodations and expenses: Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, Stemline, and Takeda.